Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial

Table 4 Adverse events occurring in ≥ 10% of the patients, n (%)

Adverse event	Grade 1-2	Grade 3-4	All grades
Alopecia	35 (79.50)	0 (0.00)	35 (79.50)
Leukopenia	22 (50.00)	2 (4.55)	24 (54.55)
Neutropenia	19 (43.18)	4 (9.09)	23 (52.27)
Liver dysfunction	18 (40.91)	0 (0.00)	18 (40.91)
Hyperbilirubinemia	16 (36.36)	2 (4.55)	18 (40.91)
Anemia	14 (31.81)	2 (4.55)	16 (36.36)
Neurotoxicity	10 (22.71)	2 (4.55)	12 (27.27)
ST-T abnormal change	9 (20.45)	0 (0.00)	9 (20.45)
Sinus tachycardia	6 (13.64)	0 (0.00)	6 (13.64)
Anorexia	5 (11.36)	0 (0.00)	5 (11.36)